BIIB
NASDAQ
$199.95
Biogen Inc (BIIB)
Biogen Inc. is an American multinational biotechnology company based in Cambridge, Massachusetts, specializing in the discovery, development, and delivery of therapies for the treatment of neurological diseases to patients worldwide.
Sector:
Healthcare
Industry:
Drug Manufacturers - General
Buy
Target: $226.29 (+13.17%)
Market Cap
$29B
PEG Ratio
0.64
Forward P/E
14.75
P/E Ratio
17.41
Price Chart
Valuation
Market Cap$29B
P/E17.41
Forward P/E14.75
PEG0.64
P/S2.93
P/B1.52
Profitability
Total Revenue (TTM)$9.94B
Gross Profit (TTM)$7.82B
EBITDA$2.70B
Profit Margin12.9%
EPS$11.33
Financial Health
Debt-to-Equity33.7%
Free Cash Flow Yield8.35%
Growth & Risk
EPS 5Y CAGR-15.32%
Revenue 5Y CAGR-4.64%
FCF 5Y CAGR-5.20%
Beta (5Y)0.51
Sharpe Ratio1.30